Objective: The aim of this study was to analyze the determinants of breast discomfort among postmenopausal women initiating menopausal hormone therapy (HT).
C yclical breast discomfort is a common symptom among premenopausal women; it may interfere with sexual, physical, social, work, and school activities. 1, 2 However, the prevalence and determinants of breast discomfort among postmenopausal women are not well understood. The prevalence of breast discomfort decreases significantly with age 3 and with the completion of the menopausal transition. 4<6 In the Melbourne Women's Midlife Health Project, the menopausal transition stage at which the prevalence of breast discomfort changed the most was between early and late perimenopause. The prevalence of breast discomfort was 21% lower in late perimenopause compared with early perimenopause. 4 The cyclic nature of breast discomfort among premenopausal women and the decline in the prevalence of breast tenderness through the menopausal transition suggest that changes in circulating sex steroid levels may influence the occurrence of breast discomfort. Moreover, breast discomfort is a recognized adverse effect of menopausal hormone therapy (HT). 3, 7, 8 Certain factors may influence the occurrence of new-onset breast discomfort during administration of HT. First, factors that are associated with altered sex steroid metabolism might alter the odds of experiencing new-onset breast discomfort during administration of HT. For example, among women initiating oral HT, on-treatment estradiol level 9<16 and estrone level 9, 14, 15, 17 increase to a lesser degree among smokers than among nonsmokers, possibly because of the increased hepatic metabolism of estrogens among smokers. 15 Similarly, through its influence on sex steroid metabolism (eg, increased peripheral aromatization of androstenedione to estrone) and by increasing on-treatment estrogen levels during HT, 18 higher weight may increase the risk of developing breast discomfort during HT. Finally, higher physical activity is associated with lower serum estrogen levels, 19 and alcohol intake increases on-treatment estrogen levels during HT, 17 suggesting that physical activity and alcohol intake levels may influence the effects of HT on breast discomfort.
Other factors may affect susceptibility to new-onset breast discomfort during HT. Inclusion of a progestogen regimen along with estrogen increases the risk of HT-associated breast discomfort. 7 ,20<22 Also, >-tocopherol supplementation has been used by clinicians as a treatment for mastalgia and has been tested in randomized controlled trials of premenopausal women with cyclic mastalgia. 23, 24 Whether >-tocopherol intake is associated with breast discomfort among postmenopausal women is unknown. Finally, because they have already been exposed to HT, recent users of HT may have decreased susceptibility to new-onset breast discomfort upon HT reinitiation.
We analyzed baseline and 12-month data from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, a randomized controlled trial of placebo versus HT in postmenopausal women, to determine the associations between smoking, body weight, alcohol consumption, age, recent use of HT, >-tocopherol intake, and physical activity and change in serum estrone level. We then examined whether smoking, body weight, alcohol consumption, age, recent use of HT, >-tocopherol intake, and physical activity were associated with the new-onset breast discomfort after initiation of HT and whether these associations were mediated by a change in serum estrone level.
METHODS

Participants
We analyzed data from the PEPI Trial, a randomized controlled trial that has been described in detail previously. 25 The PEPI Trial was designed to compare the effects of placebo and several menopausal HT regimens on cardiovascular risk factors among postmenopausal women. Participants were recruited at seven centers: George Washington University, Washington, DC; Johns Hopkins University, Baltimore, MD; Stanford University, Stanford, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; University of Iowa, Iowa City, IA; and University of Texas Health Science Center, San Antonio, TX. For inclusion, participants were required to be between 45 and 64 years old and at least 1 year postmenopausal with a folliclestimulating hormone level of 40 mIU/mL or higher. Women with a major contraindication (such as breast cancer) to the use of estrogen or progestin therapy were excluded. 25 Women using HT at study recruitment were required to stop their privately prescribed menopausal HT at least 2 months before their first screening visits (Bquitting HT for PEPI Trial[).
Of the 1,557 women screened for inclusion in the PEPI Trial, 875 met the inclusion criteria and were randomized to one of five treatment regimens. The treatment regimens were placebo, conjugated equine estrogens (CEE) 0.625 mg/day, daily CEE plus medroxyprogesterone acetate 10 mg/day for 12 days per month, daily CEE plus medroxyprogesterone acetate 2.5 mg/day continuously, and daily CEE plus micronized progesterone 200 mg/day for 12 days per month. The human research review boards at each study site approved the PEPI Trial protocol. Informed consent was obtained from all participants.
Because the focus of the current analysis was to describe the predictors of new-onset breast discomfort according to whether women were assigned to and taking one of the four active regimens, we excluded 82 PEPI Trial participants who reported having breast discomfort at baseline. Of the remaining 793 participants, 679 women took at least 80% of their assigned treatment at both the 6-and 12-month followup visits. At the 12-month follow-up visit, information was missing regarding breast symptoms for four participants and alcohol and >-tocopherol intake for one participant. For an additional 12 participants, information was missing regarding other key covariates. Thus, 662 women comprised the final analytic sample for this study.
Questionnaire and anthropometric assessments
Information about age, ethnicity, cigarette smoking, alcohol use, physical activity level, ethnicity, age at menopause, smoking, reproductive history, hysterectomy, oophorectomy, and prior use of HT was obtained from standardized self-report questionnaires at baseline and the 12-month follow-up. 25 For women who reported spontaneous menopause, age at menopause was based on self-reported age at last menstrual period. For women who had undergone bilateral oophorectomy, we assigned age at oophorectomy to be the age at menopause. Women who had hysterectomy without oophorectomy, women who reported removal of one ovary, and women who were uncertain how many ovaries were removed at time of hysterectomy were considered to have uncertain age at menopause.
Adherence to treatment assignment was defined as taking at least 80% of study medication at both the 6-and 12-month follow-up visits (verified by pill count). We defined cigarette smokers as participants who reported current smoking at both baseline and the 12-month follow-up.
Specific questions regarding breast discomfort were asked at baseline and the 12-month follow-up: BDuring the past week including today, did any of these symptoms bother you or interfere with your life? Breast sensitivity/tenderness (yes or no), painful breasts (yes or no).[ We classified women who reported one or more of these breast symptoms (sensitivity, tenderness, and pain) as having Bbreast discomfort. [ At the 12-month follow-up, participants completed the Block Food Frequency Questionnaire assessing usual food intake in the past year. 26, 27 The Block questionnaire allowed quantification of average dietary >-tocopherol intake (milligrams per day) and average daily alcoholic beverage intake (grams per day) in the past 12 months.
At the 12-month follow-up visit, home, work, and leisure physical activities in the past 12 months were quantified using an intensity-based form (Appendix). 28, 29 Examples of intensity levels were offered on the questionnaire (1, inactive; 2, light; 3, moderate; 4, heavy). Because work activity was not applicable for 85 women, we focused on leisure and home physical activity in this analysis. In addition, the physical activity questionnaire at the 12-month follow-up visit asked, BDo you regularly engage in strenuous exercise or hard physical labor? (yes or no). [ At baseline and the 12-month follow-up, using standardized techniques, weight (kilograms) and height were measured for calculation of body mass index (BMI; kilograms per meter squared). 30 
Serum estrone assay
At baseline and at the 12-month follow-up visit, fasting blood samples were obtained between 7 AM and 10 AM. The serum estrone level was measured by radioimmunoassay after organic solvent extraction and Celite column chromatography. 31 The sensitivity of the assay was 4.0 pg/mL; intra-assay and interassay coefficients of variation were 6% and 9%, respectively. Information regarding baseline or 12-month values of serum estrone was missing for eight participants (eight women in the placebo group and four women in the CEE + progestogen group).
Statistical analysis
As previously reported, 7 reports of new-onset breast discomfort at 12 months among the three progestogen-containing treatment arms were similar to each other and higher than those of CEE recipients (Table 1) . Therefore, we grouped the participants of the progestogen-containing arms together and considered treatment arm as a three-level covariate: placebo, CEE alone, and progestogen-containing regimen (ie, CEE + progestogen).
We first used linear regression to determine the associations between change in serum estrone level (12 mo minus baseline) and each of the factors of interest: age, cigarette smoking, >-tocopherol intake, alcohol intake, quitting HT for PEPI Trial, and physical activity. For the four women whose baseline estrone values were below the lower limit of detection, we assigned an estrone level of 2 pg/mL. (No 12-mo estrone values were below the lower limit of detection.)
Using logistic regression, we first examined unadjusted associations between new-onset breast discomfort (yes/no) and each of the predictors of interest: age, cigarette smoking, >-tocopherol intake, alcohol intake, quitting HT for PEPI Trial, and physical activity. 3,16,19,32<52 Because the distribution of alcohol intake was skewed, we considered alcohol intake as a binary variable (daily number of alcoholic drinks 9 median vs e median). We evaluated >-tocopherol intake both as a binary variable (daily intake 9 median vs e median) and as a continuous variable (milligrams per day). We evaluated body mass both as weight (kilograms) and as BMI (kilograms per meter squared). The linearity of the relationship between weight and log odds of having breast discomfort was confirmed using restricted cubic splines regression separately in each arm. Physical activity score ([average of Assessed at the 12-month follow-up. In the subset of women reporting any alcohol use, mean (SD) intake was 9.5 (12.5) g/day, and median intake was 5.4 g/day. For women with bilateral oophorectomy, menopause was considered to occur at the time of oophorectomy. There were 158 women for whom the number of years since menopause was not classifiable because they underwent hysterectomy without bilateral oophorectomy. c Physical activity score = ([leisure physical activity + home physical activity]/2) j 1, based on self-assessment questionnaire.
d Self-report of engaging in strenuous exercise or hard physical labor (yes vs no) assessed at the 12-month follow-up. e Women using menopausal hormone therapy at study recruitment were allowed to join the trial if they stopped privately prescribed menopausal hormone therapy at least 2 months before the first screening visit. f Months elapsed since menopausal hormone therapy use in those participants who stopped hormone therapy to join the PEPI Trial (n = 206). g Women reporting breast sensitivity, tenderness, and/or breast pain at the 12-month follow-up and absence of any of these symptoms at baseline. leisure score and home score] j 1) was less strongly associated with new-onset breast tenderness than was the binary (yes/no) question relating to strenuous physical activity. Therefore, we used strenuous activity as the indicator of physical activity in the subsequent multivariable logistic regression analyses.
We used multivariable logistic regression to determine the association between each predictor and new-onset breast discomfort (yes/no) after simultaneous adjustment for all other covariates. Interaction terms were chosen a priori based on previous publications and biological plausibility as follows. 7,9<22 To test whether the effects of the predictors varied according to treatment assignment, interaction terms for treatment arm Â physical activity, treatment arm Â cigarette smoking, treatment arm Â BMI, treatment arm Â alcohol intake, and treatment arm Â quitting HT for PEPI Trial were considered for inclusion in multivariable logistic regression models. To select which interaction effects to retain in the regression models, we used a backward stepwise procedure with P G 0.1 as the retention criterion for interaction effects and a threshold of P G 0.25 for main effects. Because of the model selection process, the following variables were included in the final multivariable logistic regression models: weight, strenuous exercise, quitting HT for PEPI Trial, and interactions of treatment assignment with weight, strenuous exercise, and quitting HT for PEPI Trial.
To explore whether change in serum estrone level from baseline to the 12-month follow-up could explain associations between predictors and new-onset breast discomfort, we added change in log serum estrone level to the multivariable logistic regression models that included the predictors that were significantly associated with new-onset breast discomfort.
In secondary analyses, we repeated our final models in the subgroup of participants for whom we had complete information regarding age at menopause (n = 505).
Sensitivity, specificity, and accuracy were computed under the logistic regression model using the receiver operating characteristic curve analysis. Accuracy was defined as the unweighted average of the specificity and the sensitivity. For each participant, we computed the predicted probability of reporting new-onset breast discomfort and the corresponding sensitivity, specificity, and accuracy. We examined the values of sensitivity and specificity that maximized the accuracy.
Statistical analyses were performed with SAS version 9.1 (SAS Institute Inc, Cary, NC). All statistical tests were two sided.
RESULTS
In participants in the analytic sample, mean age was 57.1 years, mean >-tocopherol intake was 7.2 mg/day, and mean alcohol intake was 6.0 g/day (approximately 0.43 drinks per day because a drink of alcohol typically contains about 14 g of alcohol 53 ). Median BMI was 24.9 kg/m 2 (Table 1) . Sixtyseven percent of the participants had low physical activity scores. Approximately 12% of the participants were current cigarette smokers (ie, reported smoking at both baseline and the 12-mo follow-up). Approximately one third of participants had quit menopausal HT to join the PEPI Trial (Table 1) . As has been previously reported, 7 new-onset breast discomfort was more common among women taking CEE + progestogen (28.7%) compared with women taking CEE alone (13.7%) or placebo (11.7%, Table 1 ).
Mean changes in serum estrone level from baseline to 12 months were as follows: placebo group, j0.98 pg/mL; CEE-only group, 108.48 pg/mL; and CEE + progestogen group, 101.46 pg/mL. Table 2 shows that increased weight was inversely associated with change in log serum estrone level. For each 10-kg higher weight, the serum estrone level declined by 0.08 pg/mL (P G 0.001 for the CEE-only and CEE + progestogen groups). Strenuous exercise was marginally associated with increases in serum estrone level among women assigned to CEE + progestogen therapy (P = 0.06). Table 3 displays the odds of developing new-onset breast discomfort associated with each potential predictor in the unadjusted (model 1) and adjusted (model 2) logistic regression models. In the unadjusted models, among women assigned to CEE + progestogen, strenuous exercise was associated with significantly decreased odds of new-onset breast discomfort (odds ratio [OR], 0.53; 95% CI, 0.30-0.91; Table 3 , model 1). Also, weight was inversely associated with new-onset breast discomfort among women assigned to CEE only (OR, 0.94; 95% CI, 0.90-1.00). Other factors were not significantly associated with new-onset breast discomfort among women assigned to active therapy in unadjusted models.
However, in the adjusted models, the associations of newonset breast discomfort with weight, strenuous exercise, and quitting HT for PEPI Trial varied by treatment arm (P int in Table 3 ). Therefore, we present separate OR estimates for each treatment arm resulting from logistic regression models adjusted for weight, strenuous exercise, and quitting HT for the PEPI Trial (Table 3 , model 2). In women taking CEE + progestogen, strenuous exercise was associated with a 49% lower odds of new-onset breast discomfort (OR, 0.51; 95% CI, 0.29-0.89), whereas in women taking placebo or CEE alone, strenuous exercise was not significantly associated with new-onset breast discomfort (model 2). Among women taking CEE alone, each kilogram higher weight was associated with a 6% lower odds of new-onset breast discomfort among women assigned to CEE alone (OR, 0.94; 95% CI, 0.90-1.00) and among women assigned to CEE + progestogen (OR, 0.99; 95% CI, 0.97-1.01; not statistically significant). In contrast, in women taking placebo, the association of weight with new-onset breast discomfort was in the opposite direction: each additional kilogram of weight was associated with 4% higher odds of new-onset breast discomfort (OR, 1.04; 95% CI, 1.00-1.09; model 2). There was no significant association between quitting HT for the PEPI Trial and odds of newonset breast discomfort in any treatment group. However, there was a suggestion of a lower odds of new-onset breast discomfort among women who had quit HT for the PEPI Trial compared with women who had not quit HT for the PEPI Trial among those who took CEE + progestogen (OR, 0.66; P = 0.08 in the adjusted model; and OR, 0.64; P = 0.06 in the unadjusted model); in contrast, the odds of new-onset breast discomfort were (nonsignificantly) higher among placebo and CEE users who had quit HT for the PEPI Trial.
These differences probably account for the statistical interaction between quitting HT for PEPI Trial and use of CEE + progestogen during the PEPI Trial that was noted in Table 3 (P int column).
Weight was more strongly associated with breast discomfort than was BMI, but the results of the multivariable adjusted models using BMI instead of weight were qualitatively similar to those using weight (data not shown).
Adding $ log serum estrone level (12 mo minus baseline) to the multivariable adjusted models had negligible effects on the OR estimates for the main predictors (Table 3, model 3) .
We performed a secondary analysis of participants for whom we had information regarding years since menopause. Information regarding years since menopause was missing or unknown in 158 (23.8%) of our 662 participants because they underwent hysterectomy before menopause but had at least one ovary left intact. Results of the multivariable analysis that restricted the participants with known years since menopause yielded similar findings to those of the primary analysis (data not shown). The sensitivity, specificity, and accuracy of the final model (adjusting for treatment arm, weight, strenuous exercise, quitting HT for the PEPI Trial, and interaction terms) in predicting new-onset breast discomfort were 79%, 49%, and 64%, respectively.
DISCUSSION
Among women initiating CEE + progestogen or CEE only, higher weight was associated with significantly less ontreatment increase in serum estrone level; also, strenuous exercise was associated with a marginally significantly greater increase in estrone level among women initiating CEE + progestogen therapy. Higher body weight was associated with decreased odds of new-onset breast discomfort, especially among women taking CEE alone. Strenuous exercise was associated with decreased odds of new-onset breast discomfort; the magnitude of reduction in odds among women taking CEE + progestogen was similar to that of women taking CEE alone.
Although measures of increased body mass have been associated with increased estrogen levels among postmenopausal women in prior studies, 37,38,40<42,48,49,54<72 we found weight to be inversely correlated with on-treatment change in estrone level. In line with these findings, we found that higher body weight was associated with decreased odds of new-onset breast discomfort after HT initiation. Although the reduction in the odds of new-onset breast discomfort associated with higher body weight was not statistically significant in women taking CEE + progestogen, the magnitude of the OR estimate was similar to that of women taking CEE alone, and the association of CEE + progestogen with newonset breast tenderness was statistically significantly different from that for placebo. We did not expect these results because most circulating estrogen in postmenopausal women is produced by peripheral conversion of androgens, 68 and obesity results in increased production of estrogen from androstenedione. 57, 60, 73, 74 Perhaps the decreased odds of new-onset breast discomfort that we observed with increasing body weight is due to chronic exposure to higher local estrogen production, which in turn makes the breast less susceptible to the effects of exogenous estrogen administration. To our knowledge, only one prior study focused on the influence of body weight or related measures on breast pain during administration of CEE-containing regimens. After 1 year of treatment, BMI had no significant effect on changes from baseline in breast pain in the Women's Health, Osteoporosis, Progestin, Estrogen (Women's HOPE) trial, which included the same dosing and similarly aged women as those in the PEPI Trial. 75 The discrepancy across studies may be partially due to differing questions used to ascertain breast discomfort; the prior publication did not include details regarding the text of questions used to ascertain breast discomfort. Our use of weight as a continuous variable may have allowed enhanced sensitivity to detect associations of weight with new-onset breast discomfort; the prior study classified results according to a categorical method (BMI, G25 vs Q25 kg/m 2 ). In contrast to the results in the active therapy groups, our findings among women in the placebo group were as hypothesized: weight was not inversely associated with change in estrone level, and increased weight was not associated with decreased odds of new-onset breast discomfort among women assigned to placebo. Surprisingly, we found physical activity to be marginally associated with increases in estrone level among women assigned to CEE + progestogen therapy. Despite this finding, among women taking either CEE + progestogen or CEE alone, strenuous exercisers were approximately 50% less likely to experience new-onset breast discomfort after 12 months compared with women reporting no strenuous exercise. These results are in contrast with previously reported influences of physical activity on circulating estrogen levels. A randomized controlled trial showed that a combination of homebased and facility-based physical activity intervention in postmenopausal women decreased serum estrone levels and free estradiol levels significantly compared with a control stretching intervention. 19 Thus, the risk of developing newonset breast discomfort among women initiating CEEcontaining therapy may not correspond with, or act directly via, increases in serum estrone levels.
Women who quit HT to join the PEPI Trial may have had a lower odds of developing new-onset breast discomfort after initiation of CEE + progestogen, perhaps because breast tissue that is accustomed to the effects of exogenous CEE + progestogen is less likely to become tender upon reexposure.
Because adjustment for change in serum estrone had negligible effects on associations between strenuous exercise, quitting HT for PEPI Trial, weight, and new-onset breast discomfort, the associations are unlikely to be explained by on-treatment change in serum estrone level. This may be because interindividual differences in new-onset breast discomfort depend, in large part, on the metabolism of sex steroids locally, that is, on local metabolism in breast tissue, which is not fully accounted for with adjustment for serum estrone level. All of the enzymes that convert circulating estrogen precursors into estradiol (3A-hydroxysteroid dehydrogenase, 17A-hydroxysteroid dehydrogenase, and aromatase) are present in normal breast tissue, as is steroid sulfatase (which converts estradiol sulfate to estradiol). 76 We did not find age or cigarette smoking to be a significant predictor of HT-associated breast discomfort, despite the lesser gains in serum estrone level experienced by smokers compared with nonsmokers during HT. 17 Randomized controlled trials of HT regimens other than ours have implicated older age to be positively associated 77, 78 and smoking to be inversely associated 11 with risk of HT-associated breast discomfort. The use of different HT preparations, 11, 77, 78 the earlier assessment of breast discomfort (eg, at 10 wk after HT initiation 78 ), older age of participants, 77 and higher numbers of women who smoke in prior studies may explain the discrepancy in results of the current study compared with those of prior studies. Moreover, we found no evidence that newonset breast discomfort was influenced by dietary >-tocopherol intake among postmenopausal women assigned to CEE alone or CEE + progestogen therapy. Our results showing a lack of association between >-tocopherol intake and new-onset breast discomfort are consistent with the lack of benefit of >-tocopherol in relieving cyclical breast discomfort in randomized controlled trials of premenopausal women. 23, 24 Although a prior PEPI Trial study demonstrated that increases in serum estrone levels after 12 months of CEEcontaining HT were 15% greater among women who drank more than 5.5 g/day of alcohol than among women who drank 5.5 g/day of alcohol or less, 17 the current study does not support an influence of self-reported alcohol intake on the occurrence of HT-associated breast discomfort.
We seem to report a higher prevalence of new-onset breast discomfort compared with the large Women's Health Initiative Estrogen Plus Progestin Clinical Trial, which reported a prevalence of 9.3%. 3 However, the former report, which randomized postmenopausal women with an intact uterus to CEE 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily or placebo, quantified only moderate or severe breast tenderness, whereas we included women with any severity (mild, moderate, or severe) of breast tenderness in the current report. It is likely that heterogeneity regarding how questionnaires assess breast symptoms and what degrees of severity are included in statistical analyses result in different prevalence estimates for HT-associated breast symptoms across studies.
Strengths of our study include the exclusion of data from participants with baseline breast discomfort (optimizing the reliability of the estimate of new-onset breast discomfort); the ability to compare placebo, CEE alone, and CEE + progestogen; and the blinded method of collection of information regarding breast discomfort that was identically applied to all participants. Our study has limitations. Our assessments of >-tocopherol intake, alcohol intake, and physical activity levels may not have been as reliable as that which would have been afforded by prospectively collected diaries.
CONCLUSIONS
In conclusion, strenuous exercise and higher body weight may decrease the odds of new-onset breast discomfort among postmenopausal women initiating CEE-containing HT. Determinants of new-onset breast discomfort during HT administration and the mechanisms by which they act to induce breast discomfort require further elucidation.
